Research and Markets: Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/fvcpcj/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering.

TechNavio's analysts forecast the global tissue engineering and cell therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in R and D. The global tissue engineering and cell therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market.

The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc.

The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeolus Pharmaceuticals Inc., Aldagen Inc., Alexion Pharmaceuticals Inc., Angioblast Systems Inc., Angiotech Pharmaceuticals Inc., ARIAD Pharmaceuticals Inc., Arteriocyte Medical Systems Inc., Athersys Inc., AVAX Technologies Inc., Avita Medical Ltd., Biocoral Inc., Bioheart Inc., BioLife Solutions Inc., BioMimetic Therapeutics Inc., BioSante Pharmaceuticals Inc., BioSyntech Inc., BioTissue Technologies AG, Boston Scientific Corp., Brainstorm Cell Therapeutics Inc., California Stem Cell Inc., Capricor Inc., Capstone Therapeutics Corp., Celgene Corp., CellSeed Inc., Cellular Dynamics International Inc., Cerco Medical LLC, co.don AG, ConMed Linvatec Biomaterials Inc., Cook Group Inc., CryoLife Inc., Curis Inc., Cyclacel Pharmaceuticals Inc., Cytograft Tissue Engineering Inc., Cytomatrix Inc., Cytori Therapeutics Inc., Exactech Inc., Excorp Medical Inc., FibroGen Inc., Fidia Advanced Biopolymers S.r.l., Genta Inc., Genzyme Corp., Geron Corp., Hospira Inc., Integra LifeSciences Holdings Corp., Johnson and Johnson, Kinetic Concepts Inc., Musculoskeletal Transplant Foundation Inc., OSI Pharmaceuticals Inc., Organogenesis Inc., Osteotech Inc., RTI Biologics Inc., and Smith and Nephew plc.

Commenting on the report, an analyst from TechNavio's Healthcare team said: "The Global Tissue Engineering and Cell Therapy market is witnessing an increase in mergers and acquisitions among the global and regional vendors. There has been a significant increase in the acquisition of small and medium-sized companies by the leading tissue engineering and regenerative medicine developers."

According to the report, one of the major factors driving the global tissue engineering and cell therapy market is the significant developments in RandD. Most of the applications in tissue engineering are at their nascent stage. Therefore, reputable vendors are investing more in RandD to evolve with more patents in the global tissue engineering and cell therapy market.

For more information visit http://www.researchandmarkets.com/research/fvcpcj/global_tissue

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices